Anzeige
Mehr »
Dienstag, 07.07.2026 - Börsentäglich über 12.000 News
Crypto.com-Paukenschlag!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AFXS | ISIN: US2210151005 | Ticker-Symbol: C17
Tradegate
06.07.26 | 17:42
13,675 Euro
+3,01 % +0,400
1-Jahres-Chart
CORVUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CORVUS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
13,65013,73022:16
13,47013,89522:00

Aktuelle News zur CORVUS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.06.Corvus Pharmaceuticals, Inc. - 8-K, Current Report4
09.06.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China232SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in...
► Artikel lesen
14.05.Corvus Pharmaceuticals, Inc. - 8-K, Current Report12
CORVUS PHARMACEUTICALS Aktie jetzt für 0€ handeln
07.05.Corvus Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
23.04.Corvus Pharmaceuticals, Inc. - 8-K, Current Report2
23.04.Corvus Pharmaceuticals appoints ex-Genentech executive to board1
23.04.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors256SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D.,...
► Artikel lesen
21.04.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting1
17.04.Goldman Sachs initiates Corvus Pharmaceuticals stock with buy rating9
17.04.Goldman Sachs startet Coverage für Corvus Pharmaceuticals mit Kaufempfehlung35
13.03.Corvus Pharmaceuticals, Inc. - 8-K, Current Report5
13.03.Cantor Fitzgerald reiterates Corvus Pharmaceuticals stock rating4
13.03.Cantor Fitzgerald bestätigt "Overweight"-Rating für Corvus Pharmaceuticals10
13.03.Oppenheimer hebt Kursziel für Corvus Pharmaceuticals auf 33 US-Dollar an6
13.03.Oppenheimer raises Corvus Pharmaceuticals stock price target to $332
12.03.Corvus Pharmaceuticals verfehlt EPS-Prognose für Q4 2025 - Aktie gibt nach1
12.03.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results774Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated...
► Artikel lesen
12.03.Corvus Pharmaceuticals, Inc. - 10-K, Annual Report2
05.03.Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 20262
27.01.If You Invested $1000 In Corvus Pharma Stock 5 Years Ago, You Would Have This Much Today7
Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1